Skip to main content

Table 1 Patients characteristics

From: The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas

  AA
n = 23
GBM
n = 116
Age in years
 Median 50 65
 Range 25–74 26–81
 Age (> 65, <= 65) 6, 17 63, 53
Gender (male/female) 13, 10 (1.30:1.00) 69, 47 (1.49:1.00)
Extent of resection
 GTR 14 (61%) 89 (77%)
 STR 5 (22%) 25 (22%)
 Biopsy only 4 (17%) 1 (1%)
 N.d. 0 1 (1%)
KPS (> 70, <= 70, n.d.) 15 (65%), 6 (26%), 2 (9%) 42 (36%), 73 (63%), 0
IDH +, IDH - 13 (57%), 10 (43%) 6 (5%), 110 (95%)
MGMT+, MGMT-, MGMT n.d. 20 (87%), 3 (13%), 0 43 (37%), 71 (61%), 2 (2%)
IDH+ & MGMT+ 12 (52%) 6 (26%)
IDH- & MGMT- 2 (7%) 71 (61%)
IDH+ & MGMT- 1 (4%) 0
IDH- & MGMT+ 8 (35%) 37 (32%)
EGFR+, EGFR -, EGFR n.d. 5 (50%), 5 (50%), 0 53 (46%), 61 (54%), 3 (2%)
  1. AA anaplastic astrocytoma, GBM glioblastoma, GTR gross total resection, STR subtotal resection, n.d. not determined, KPS Karnofsky Performance Scale, IDH+ IDH1 or IDH2 mutation, IDH- no IDH1 or IDH2 mutation, MGMT+ promoter methylation, MGMT- no promoter methylation, EGFR+ amplification, EGFR- no amplification